Agemica founder recognized in King Charles III’s Birthday Honours as his AI-driven longevity platform advances toward in vivo testing.
Professor Ronjon Nag, founder and CEO of longevity therapeutics company Agemica, has been appointed an Officer of the Order of the British Empire (OBE) in King Charles III’s Birthday Honours, being recognized for services to entrepreneurship and artificial intelligence [1].
The Birthday Honours are one of two major honours lists published each year as part of the UK’s national honors system, recognizing contributions across science, business, public service and the arts. While the award reflects Nag’s broader career in AI and technology entrepreneurship, it arrives at a moment when his attention is increasingly focused on aging biology and the application of artificial intelligence to age-related disease.
From speech recognition to aging biology
Nag’s career spans four decades of AI development. Having built an early speech-recognition system while an undergraduate at the University of Birmingham, he went on to study at Cambridge, MIT and Stanford, later founding companies whose technologies contributed to speech, handwriting recognition and predictive text systems adopted across the mobile industry.
Today, through Agemica, he is applying those computational tools to a different challenge: identifying biological targets shared across multiple age-related conditions and designing immune-based interventions intended to address them at scale.
Longevity.Technology: An OBE may come wrapped in velvet, ceremony and a pleasingly British amount of heraldic admin, but the more interesting signal here is not the gong itself – it is what, and who, is now being recognized. Nag’s career traces a line from early AI systems for speech and handwriting to AI-designed biology, and that arc mirrors a broader shift in longevity biotech: artificial intelligence is no longer just a useful tool at the edge of discovery, but part of the infrastructure by which aging biology is being mapped, modeled and, eventually, therapeutically interrogated. While Agemica’s work remains preclinical, and immune-training approaches targeting shared drivers of age-related disease must still clear the hurdles of in vivo validation, safety and translatability, when honors for entrepreneurship and AI begin to intersect with serious healthspan science, it suggests the field is moving from eccentric future-gazing toward something more economically, politically and clinically consequential. Which is rather the point – aging was never going to sit quietly in its biomedical box.
An immune-centered approach
Agemica is developing an AI-designed immune-training platform based on the premise that many chronic diseases share underlying biological mechanisms. Rather than pursuing individual conditions in isolation, the company is attempting to identify common molecular targets linked to cancer, neurodegenerative, cardiovascular and metabolic disorders.
The platform combines proprietary AI systems with an mRNA-based architecture intended to encode large numbers of selected immune targets. The work remains at the preclinical stage. According to the company, ex vivo studies demonstrated tumor reduction across 13 cancer types using AI-designed peptides, while several proprietary drug combinations produced synergistic effects across multiple cancer models.
“The methods we struggled to apply to speech and handwriting forty years ago are now, in far more powerful form, reshaping biology,” Nag said. “Instead of fighting diseases one at a time, we’re using AI to design vaccines that train the immune system against the drivers many of them share.”
Validation ahead
The next milestone for Agemica is in vivo validation using humanized mouse models, with pancreatic cancer among the initial targets. The company was selected for Stanford Medicine’s Big Ideas in Medicine program in 2023 and is currently competing in the $101 million XPRIZE Healthspan competition.
Nag is careful not to overstate the current stage of development. “It’s early, and there’s a lot of validation ahead,” he said. “But the convergence of AI, systems biology and vaccine technology is a genuine opportunity, and it’s the work I care most about.”
Converging disciplines
For longevity biotechnology, the significance may lie less in any single platform than in the growing convergence of disciplines once considered distinct. AI researchers are becoming drug developers; computational scientists are entering geroscience; longevity is increasingly attracting expertise from fields that matured far from the laboratory bench. The boundaries are becoming porous, and perhaps the field is growing up.
READ MORE – ‘A vaccine for aging in under ten years’ with Ronjon Nag
